Brokers Issue Forecasts for ASND FY2025 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Ascendis Pharma A/S in a research report issued to clients and investors on Tuesday, February 25th. Cantor Fitzgerald analyst L. Watsek anticipates that the biotechnology company will earn ($2.72) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $200.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($4.34) per share.

Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Oppenheimer decreased their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. TD Cowen lowered their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. The Goldman Sachs Group upped their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and a consensus price target of $202.36.

Ascendis Pharma A/S Stock Up 0.3 %

Shares of ASND opened at $153.14 on Thursday. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $157.37. The stock has a market cap of $9.29 billion, a PE ratio of -21.57 and a beta of 0.64. The firm’s fifty day moving average is $135.70 and its two-hundred day moving average is $133.80.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ASND. T. Rowe Price Investment Management Inc. lifted its stake in Ascendis Pharma A/S by 54.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company’s stock worth $375,226,000 after purchasing an additional 960,504 shares during the last quarter. Capital International Investors lifted its position in shares of Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock worth $394,183,000 after buying an additional 753,859 shares during the last quarter. Groupama Asset Managment purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth approximately $60,000. RA Capital Management L.P. boosted its holdings in shares of Ascendis Pharma A/S by 4.1% in the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock valued at $1,392,221,000 after buying an additional 402,316 shares in the last quarter. Finally, Vestal Point Capital LP grew its position in shares of Ascendis Pharma A/S by 108.0% in the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company’s stock valued at $71,588,000 after buying an additional 270,000 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.